ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1837

KL-6, CXCL11 and CTGF Are Potential Biomarkers in Response to Treatment in CTD-ILD

Yu-Hsiang Chiu1, Mareye Voortman1, Eveline Delemarre1, Stefan Nierkens1, Pim de Jong1, Firdaus Mohamed Hoesein1, Jan Grutters2, Jacob van Laar1 and Julia Spierings3, 1University Medical Centre Utrecht, Utrecht, Netherlands, 2St. Antonius Hospital, Nieuwegein, Netherlands, 3University Medical Center Utrecht, Utrecht, Netherlands

Meeting: ACR Convergence 2021

Keywords: autoimmune diseases, Biomarkers, chemokines, cytokines, interstitial lung disease

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 9, 2021

Title: Systemic Sclerosis & Related Disorders – Clinical Poster III (1836–1861)

Session Type: Poster Session D

Session Time: 8:30AM-10:30AM

Background/Purpose: Connective tissue disease related interstitial lung disease (CTD-ILD) is common and an important cause of morbidity and mortality. We aimed to identify biomarkers in CTD-ILD correlating with radiographic characteristics and response to immunosuppressive therapy at one-year follow-up.

Methods: An exploratory set of 38 biomarkers were measured in serum of patients with CTD-ILD at baseline and one year of follow-up. The high resolution computed tomography (HRCT) patterns were classified according to the classification for idiopathic interstitial pneumonia and categorised into fibrotic or inflammatory. The predictivity of baseline biomarker, responsiveness of biomarkers to treatment, and correlations between the variation of biomarkers and pulmonary function test after one year of treatment were examined.

Results: Sixteen patients were included (12 females (75.0%), median age 51 years (IQR 45-62). The established CTD diagnoses, comorbidities, immunosuppressive therapies, and HRCT patterns were summarized in Table 1. Patients with inflammatory HRCT patterns showed less decline in forced vital capacity (FVC), 7.7% versus 33.3% in patients with fibrotic HRCT patterns. In patients with inflammatory HRCT patterns, CXCL11 reduced from a median 307.8 pg/ml to 253.8 pg/ml (p = 0.011), CTGF from 48.5 pg/ml to 9.5 pg/ml (p = 0.033) and KL-6 from 1221 U/ml to 543 U/ml (p = 0.040). (Figure 1) Additionally, an increase in levels of galectin-3 at one-year follow-up was associated with improved FVC (Rho 0.5, p = 0.048). (Figure 1D) A visualized baseline biomarkers heatmap showed that the biomarker concentrations are determined less by ILD but more by underlying CTD manifestations. (Figure 2)

Conclusion: In this study, CXCL11, CTGF, and KL-6 reduction were associated with inflammatory HRCT patterns and better pulmonary outcome. In contrast to previous research in severe ILD, there was a positive correlation between changes of galectin-3 and FVC in our study. Further research in a larger group and focusing on combining biomarkers to predict outcome and prognosis is needed.

Table 1. Baseline demography. Abbreviations: IQR, interquartile range; CTD, connective tissue disease; HRCT, high resolution computed tomography; HSCT, hematopoietic stem-cell transplantation; LIP, lymphocytic interstitial pneumonia; MCTD, mixed connective tissue disease; NSIP, non-specific interstitial pneumonia; OP, organising pneumonia; PPFE, pleuroparenchymal fibro-elastosis; SLE, systemic lupus erythematosus; SSc, systemic sclerosis; UCTD, undifferentiated connective tissue disease; UIP, usual interstitial pneumonia.

Figure 1. Decline in CXCL11 (A), Krebs von den Lungen 6 (KL-6) (B), and connective tissue growth factor (CTGF) (C) over one year of treatment was associated with inflammatory high resolution computed tomography (HRCT) pattern. (D) Correlation between changes of Galectin_3 (Gal3) and forced vital capacity (FVC) after one year of treatment. An increase of Galectin_3 reflected the improvement of lung function.

Figure 2. Baseline biomarkers heatmap. Hierarchical clustering of biomarkers measured at baseline was visualized in the heatmap. The concentration of each biomarker was normalized and presented in colour, the closer to red the higher. MCTD, mixed connective tissue disease; SSc, systemic sclerosis; SLE, systemic lupus erythematosus; RA, rheumatoid arthritis; UCTD, undifferentiated connective tissue disease. KL6, Krebs von den Lungen 6; sICAM, soluble intercellular adhesion molecule_1; SPD, surfactant protein D; Gal3, Galectin_3; sPD1, soluble programmed death_1; sVCAM, soluble vascular cell adhesion molecule_1; YKL40, also known as chitinase 3-like 1; TNFa, tumor necrosis factor alpha; CTGF, connective tissue growth factor; Psel, P-selectin; GMCSF, granulocyte-macrophage colony-stimulating factor; MMP, matrix metalloproteinase; SAA1, serum amyloid A1; IL1RA, interleukin (IL)_1 receptor antagonist; IFNg, interferon gamma.


Disclosures: Y. Chiu, None; M. Voortman, None; E. Delemarre, None; S. Nierkens, None; P. de Jong, Sanifit, 2, Inozyme, 2; F. Mohamed Hoesein, None; J. Grutters, None; J. van Laar, Abbvie, 6, Arxx Tx, 6, Galapagos, 6, Gesyntha, 6, Leadiant, 6, Roche, 6, Boehringer Ingelheim, 5, Astra Zeneca, 5, MSD, 5, Roche, 5; J. Spierings, Boehringer Ingelheim, 5, Miltenyi, 5.

To cite this abstract in AMA style:

Chiu Y, Voortman M, Delemarre E, Nierkens S, de Jong P, Mohamed Hoesein F, Grutters J, van Laar J, Spierings J. KL-6, CXCL11 and CTGF Are Potential Biomarkers in Response to Treatment in CTD-ILD [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/kl-6-cxcl11-and-ctgf-are-potential-biomarkers-in-response-to-treatment-in-ctd-ild/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/kl-6-cxcl11-and-ctgf-are-potential-biomarkers-in-response-to-treatment-in-ctd-ild/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology